site stats

Paratek investor relations

Web31 Dec 2024 · PARATEK PHARMACEUTICALS, INC. Condensed Consolidated Balance Sheets (unaudited) (in thousands) Condensed Consolidated Statement of Operations … Web25 Feb 2024 · Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q4 2024 Earnings Conference Call February 24, 2024 4:30 PM ETCompany Participants. Ben Strain - Vice President of Investor Relations. Evan Loh - Chief ...

Paratek Pharmaceuticals to Report First Quarter 2024 Financial …

Web10 Apr 2024 · Investor Relations GlobeNewswire Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical ... WebI am a nationally recognized communications strategist, advising the world’s most influential spokespersons. I founded CEO MEDIA COACH Inc. to … bc pushlockアンカー https://vortexhealingmidwest.com

Paratek Pharmaceuticals Announces Third Quarter 2024

WebInvestor Relations Careers Overview Learn More. The Team. Testimonials; More >> Positions Available. ... He previously served on the board of Transcept Pharmaceuticals, Inc. from April 2013 until its merger with Paratek on October 30, 2014. Previously, Dr. Dietz was a member of the research faculty in the Department of Medicine, University of ... WebParatek Pharma Email Alerts Investor Relations Investor Overview Corporate Governance Stock Information SEC Filings News Information Request RSS - SEC Filings RSS - Events … WebExecutive Chairman, Board of Directors. Evan Loh, M.D. Chief Executive Officer, Director. Adam Woodrow. President and Chief Commercial Officer. William Haskel. Chief Legal … 占い 大学

Paratek Pharmaceuticals Inc PRTK Stock Quote - Morningstar

Category:Paratek Pharma

Tags:Paratek investor relations

Paratek investor relations

Paratek Pharmaceuticals to Report First Quarter 2024 Financial …

WebApril 10, 2024. BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today ... Web7 Apr 2024 · See the latest Paratek Pharmaceuticals Inc stock price (NASDAQ:PRTK), related news, valuation, dividends and more to help you make your investing decisions.

Paratek investor relations

Did you know?

WebA disciplined team with proven capabilities in developing and commercializing new treatment options for complex medical issues. ‍ Meet Our Team Powered by You Our … WebBOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and …

Web16 Mar 2024 · Paratek routinely posts important information for investors on the Investor Relations section of its website at www.ParatekPharma.com. Paratek intends to use this website as a means of... Web27 Feb 2024 · Investor Relations EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders.

Web16 Mar 2024 · BOSTON, March 16, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate … Web25 Jul 2024 · The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 877-300-8521 and international investors should dial +1-412-317-6026. The conference ID is 10169245.

Web2 Aug 2024 · Clinical program successfully completed to support regulatory applications and potential approval in the U.S. and EUPre-NDA meetings with FDA conf...

Web3 Aug 2024 · Investor Relations: Hans Vitzthum LifeSci Advisors [email protected] Phone: 617-430-7578 Media: Christine Fanelle Scient PR [email protected] Phone: … 占い 大宮そごうWeb3 Jan 2024 · Paratek Pharmaceuticals' enterprise value of $369 million is less than 2X 2024 sales. ... Our analysts are third party authors that include both professional investors and individual investors who ... 占い 大宮Web16 May 2024 · Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or... 占い 大通Web1 Jul 2014 · /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) and Paratek Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announced today... Transcept Pharmaceuticals and... bcpx3 評価キット j80d1Web4 May 2024 · Paratek Pharmaceuticals Announces First Quarter 2024 Revenue of $24.9 Million Paratek Pharmaceuticals May 4, 2024, 4:05 PM · 10 min read Paratek Pharmaceuticals -- NUZYRA® (omadacycline)... bcp tsv インポートWeb3 Nov 2024 · Investor Relations: Hans Vitzthum LifeSci Advisors [email protected] Phone: 617-430-7578 Media: Christine Fanelle Scient PR [email protected] Phone: 215-595-5211 Paratek... bcp sqlserver オプション占い 大宮 安い